In vitro study published in the new england journal of medicine demonstrates sera from individuals immunized with the pfizer-biontech covid-19 vaccine neutralize sars-cov-2 with south african variant spike mutations

New york, ny and mainz, germany, february 17, 2021 (globe newswire) — pfizer inc. (nyse: pfe) and biontech se (nasdaq: bntx) today announced results from an in vitro study that provides additional data on the capability of sera from individuals immunized with the pfizer-biontech covid-19 vaccine (bnt162b2) to neutralize sars-cov-2 with the south african variant spike protein. this study, which builds on previous work, was conducted by pfizer and the university of texas medical branch (utmb), and results were published in the new england journal of medicine .
BNTX Ratings Summary
BNTX Quant Ranking